Nonadherence to medications by patients requiring hemodialysis (HD) leads to unfavorable clinical outcomes.Limited data exist on the influence of pharmacists on pharmacoadherence by patients requiring HD. Therefore, we assessed the impact of patient-centered pharmacist care through the implementation of concepts of Medication Therapy Management (MTM) and motivational interview (MI) on pharmacoadherence and its outcomes in patients requiring HD.
Patients were assessed at baseline for baseline characteristics, dialysis-related factors, and medications records 1. Pharmacists conducted brief monthly interview for patients to assess the medications they are receiving 2. A comprehensive interview for patients occurred at month 3 and 5 including concepts of MTM and MI 3. MTM included a review of each participant's medications and personal medication record to identify the use of any over-the-counter medications, design of their medication-related action plan, formulation of specific therapeutic interventions, and referrals for discussion with their physician and subsequent documentation and follow-up. The therapeutic interventions accepted by the physician were further discussed with each patient/caregiver using the MI technique to encourage adherence and this discussion was documented in each patient's medication record. 4. MI incorporated the main components reported in the literature: rolling with resistance; expressing empathy; avoiding argumentative behavior; highlighting the discrepancy between patients' current attitudes compared with the desired therapeutic goals; and empowering patients' self-efficacy
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
72
A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
Changes in pharmacoadherence of patients requiring HD using electronic medication refill from baseline
Comparing changes in self-reporting of number of medications with electronic prescribing during each of the six interviews
Time frame: Monthly and up to 6 months
Changes in pharmacoadherence of patients requiring HD through the control of serum phosphate level (mmol/L) from baseline
Changes in surrogate laboratory pre-HD serum phosphate level (mmol/L) from baseline
Time frame: Monthly and up to 6 months
Changes in Systolic blood pressure (SBP) control in mmHg from baseline as a independent surrogate marker for administration of medications
Changes in Systolic blood pressure (SBP) control in mmHg from baseline and on a monthly basis
Time frame: Monthly and up to 6 months
Changes in serum low-density lipoprotein (LDL) levels in mmol/L from baseline as an independent surrogate marker for the administration of medications
Changes in serum low-density lipoprotein (LDL) levels in mmol/L from baseline and on a monthly basis
Time frame: Monthly and up to 6 months
Changes in Number of Medication-related problems (MRPs) from baseline at month 3 and month 5
Number
Time frame: At month 3 and month 5 of the study
Types of Medication-related problems (MRPs)
Types of Medication-related problems included in the study as identified in literature: improper drug dosing or selection; initiation of medication without indication; adverse drug events; failure to receive drugs; indication without treatment; suggested alternative therapeutic options; and inappropriate monitoring or laboratory tests required
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Total study duration: from month 1 to month 6
Number of accepted therapeutic interventions by the pharmacist
Number of Therapeutic interventions suggested by the pharmacists to alter medication regimen suggested by pharmacist based on discussion and approval of prescribing physicians
Time frame: Monthly and up to 6 months